Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID).
University Hospitals Leuven, Department of Gastroenterology and Hepatology.
Inflamm Bowel Dis. 2021 May 17;27(6):870-886. doi: 10.1093/ibd/izaa281.
Crohn's disease (CD), a form of inflammatory bowel disease (IBD), is characterized by heterogeneity along multiple clinical axes, which in turn impacts disease progression and treatment modalities. Using advanced data integration approaches and systems biology tools, we studied the contribution of CD susceptibility variants and gene expression in distinct peripheral immune cell subsets (CD14+ monocytes and CD4+ T cells) to relevant clinical traits. Our analyses revealed that most clinical traits capturing CD heterogeneity could be associated with CD14+ and CD4+ gene expression rather than disease susceptibility variants. By disentangling the sources of variation, we identified molecular features that could potentially be driving the heterogeneity of various clinical traits of CD patients. Further downstream analyses identified contextual hub proteins such as genes encoding barrier functions, antimicrobial peptides, chemokines, and their receptors, which are either targeted by drugs used in CD or other inflammatory diseases or are relevant to the biological functions implicated in disease pathology. These hubs could be used as cell type-specific targets to treat specific subtypes of CD patients in a more individualized approach based on the underlying biology driving their disease subtypes. Our study highlights the importance of data integration and systems approaches to investigate complex and heterogeneous diseases such as IBD.
克罗恩病(CD),一种炎症性肠病(IBD)的形式,其特征是在多个临床轴线上存在异质性,这反过来又影响疾病的进展和治疗方式。我们使用先进的数据整合方法和系统生物学工具,研究了 CD 易感性变异体和特定外周免疫细胞亚群(CD14+单核细胞和 CD4+T 细胞)中的基因表达对相关临床特征的贡献。我们的分析表明,大多数捕获 CD 异质性的临床特征可以与 CD14+和 CD4+基因表达相关,而不是与疾病易感性变异体相关。通过分离变异的来源,我们确定了潜在的分子特征,这些特征可能是导致 CD 患者各种临床特征异质性的原因。进一步的下游分析确定了上下文枢纽蛋白,如编码屏障功能、抗菌肽、趋化因子及其受体的基因,这些蛋白要么是 CD 或其他炎症性疾病中使用的药物的靶点,要么与疾病病理中涉及的生物学功能相关。这些枢纽蛋白可以用作细胞类型特异性靶点,根据驱动其疾病亚型的潜在生物学,以更个体化的方式治疗特定亚型的 CD 患者。我们的研究强调了数据整合和系统方法在研究复杂和异质性疾病(如 IBD)中的重要性。